<DOC>
	<DOCNO>NCT01188252</DOCNO>
	<brief_summary>Clinical study determine safety , tolerability , measure drug metabolize body determine maximum tolerate dose BAY1000394 give intermittent 3 day / 4 day schedule patient advance malignancy</brief_summary>
	<brief_title>Clinical Study Evaluate Maximum Tolerated Dose BAY1000394 Given 3 Days / 4 Days Off Schedule Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Subjects advance , histologically cytologically confirm solid tumor , refractory standard therapy , standard therapy available , subject must actively refuse treatment would regard standard , / judgment investigator , experimental treatment clinically ethically acceptable At least 1 tumor lesion measurable computer tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord RECIST 1.1 Adequate bone marrow , liver , renal function assess follow laboratory requirement conduct within 14 day prior first dose study drug History cardiac disease : congestive heart failure &gt; NYHA Class II , unstable angina ( anginal symptom rest ) , episodes angina history myocardial infarction , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) , previous venous arterial thrombotic event , pulmonary embolism Moderate severe hepatic impairment , i.e . ChildPugh class B C ( 3 ) History human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Active clinically serious infection CTCAE &gt; Grade 2 ( CTCAE v4.02 ) Symptomatic metastatic brain meningeal tumor unless subject &gt; 3 month definitive therapy , evidence tumor growth image study within 4 week prior study entry , clinically stable respect tumor time study entry . Subjects must acute steroid therapy taper steroid therapy ( chronic steroid therapy acceptable provide dose stable 4 week prior study entry follow screen CT / MRI scan ) . Subjects neurological symptom undergo CT / MRI scan brain exclude new progressive brain metastasis . Spinal cord metastasis acceptable Seizure disorder require therapy ( steroids antiepileptic ) History organ allograft Evidence history bleed disorder , i.e . hemorrhage / bleed event CTCAE &gt; Grade 2 within 4 week prior prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Kinase inhibitor</keyword>
	<keyword>Cyclin-dependent kinase</keyword>
</DOC>